Key facts
- It has raised $3.2M; the latest was Accelerator/Incubator in May 2024.
- Notable investors include MedTech Innovator, National Institutes of Health, ATMA Capital, Beacon Angels, Auroral Holdings — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Juniper Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Juniper Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Juniper Biomedical
Developer of implantable neuromodulation systems designed to effectively and safely treat patients with pelvic health conditions. The company's technology modulates distal target nerves locally by stimulating only the target and can be used to modulate innervation to muscles or organs alike, enabling patients to avail less invasive, safer, and more effective therapy for conditions like incontinence, sexual dysfunction, and chronic pain.
- Sector
- Healthcare
- HQ
- Worcester, MA, United States
- Founded
- 2019
- Employees
- 8
- Website
- juniperbiomedical.com/
- Ownership
- Privately Held (backing)
Juniper Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juniper Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juniper Biomedical in its N-PORT filings yet. We sweep new filings monthly.